Emergent BioSolutions (STU:ER4) Accounts Payable & Accrued Expense : €105 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Accounts Payable & Accrued Expense?

Emergent BioSolutions's quarterly accounts payable & accrued expense declined from Sep. 2023 (€122 Mil) to Dec. 2023 (€120 Mil) and declined from Dec. 2023 (€120 Mil) to Mar. 2024 (€105 Mil).

Emergent BioSolutions's annual accounts payable & accrued expense declined from Dec. 2021 (€160 Mil) to Dec. 2022 (€131 Mil) and declined from Dec. 2022 (€131 Mil) to Dec. 2023 (€120 Mil).

Emergent BioSolutions Accounts Payable & Accrued Expense Historical Data

The historical data trend for Emergent BioSolutions's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Accounts Payable & Accrued Expense Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

120.87

150.43

159.83

130.65

119.94

Emergent BioSolutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															135.90	128.76	121.53	119.94	105.34

Emergent BioSolutions Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Emergent BioSolutions (STU:ER4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines